Genital Neoplasms, Male  >>  odanacatib (MK-0822)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
odanacatib (MK-0822) / Merck (MSD)
NCT00691899 / 2008-002120-29: A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Withdrawn
3
0
US
odanacatib, MK0822, placebo (unspecified)
Merck Sharp & Dohme LLC
Prostate Cancer
09/08
09/08

Download Options